Red I share your sentiment that it has indeed been a long road and I share some of your frustrations also. However, I think it simplistic to suggest that the last 9 years have all been about moving from TST to Quantiferon (well, not directly anyway).
QFT1 was not really a market winner against the TST. QFT2, the gold product was much more competitive but not a great deal of marketing effort was put into it because QFT3, the in-tube product, was already being developed.
QfT gold in-tube has realistically only been on the market for a much shorter period of time, gained FDA approval only in the last 3 years and is only this half being sold in Japan.
In this latter period we have seen exponential profit growth (until the last half, but that had its own issues). I don't know if you understand how significant this exponential profit growth is when we still have such a small market share, but to me it is very significant indeed.
You are right, the next couple of profit results will be very important, but as long as profits continue to grow then I will be happy.
I have full confidence in the marketing efforts to date and the business plan of our management to deliver significant returns on this technology well into the future.
Buying now for growing profits into the future seems a no-brainer to me.
CST Price at posting:
$2.89 Sentiment: Buy Disclosure: Held
